Abstract
Pneumonia remains an important cause of morbidity and mortality, despite advances in antimicrobial therapy. Pneumonia causes injury to the terminal alveolo-capillary unit, which is followed by increased alveolar permeability, pulmonary edema and hemorrhage, and may lead to respiratory failure. It has been demonstrated that the pulmonary surfactant system becomes impaired in pneumonia, causing decreased compliance, atelectasis, pulmonary edema, ventilation-perfusion mismatch, intrapulmonary shunting, and an impaired arterial oxygenation [1–3].
Chapter PDF
Similar content being viewed by others
References
Gommers D, Lachmann B (1993) Surfactant therapy: Does it have a role in adults? Clin Intensive Care 4: 284–295
Lachmann B, Gommers D (1993) Is it rational to treat pneumonia with exogenous surfactant? Eur Respir J 6: 1427–1428
Brogden KA (1991) Changes in pulmonary surfactant during bacterial pneumonia. Antonie van Leeuwenhoek 59: 215–223
Lachmann B (1987) The role of pulmonary surfactant in the pathogenesis and therapy of ARDS. In: Vincent JL (ed) Update in intensive care and emergency medicine 1987. Springer-Verlag, Berlin, Heidelberg, pp 123–134
Pison U, Max M, Neuendank A, Weissbach S, Pietschmann S (1994) Host defence capacities of pulmonary surfactant: Evidence for `non-surfactant’ functions of the surfactant system. Eur J Clin Invest 24: 586–599
Sutnick AI, Soloff LA (1964) Atelectasis with pneumonia. A pathophysiologic study. Ann Intern Med 60: 39–46
Holm BA (1992) Surfactant inactivation in Adult Respiratory Distress Syndrome. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant: From molecular biology to clinical practice. Elsevier, Amsterdam, pp 665–684
Kharasch VS, Sweeney TD, Fredberg J, et al (1991) Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 144: 909–913
Van ‘t Veen A, Mouton JW, Gommers D, Lachmann B (1997) Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br J Pharmacol (In press)
Johansson J, Curstedt T, Robertson B (1994) The proteins of the surfactant system. Eur Respir J 7: 372–391
Van Golde LMG (1995) Potential role of surfactant proteins A and D in innate lung defense against pathogens. Biol Neonate 67 (Suppl 1): 2–17
Rider ED (1995) Metabolism of pulmonary surfactant. Sem Resp Crit Care Med 16: 17–28
Guyton AC, Moffat DS, Adair TA (1984) Role of alveolar surface tension in transepithelial movement of fluid. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant. Amsterdam, Elsevier, pp 171–185
Lachmann B (1985) Possible function of bronchial surfactant. Eur J Respir Dis 67: 46–61
Enhorning G, Duffy LC, Welliver RC (1995) Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 151: 554–556
Liau DF, Yin NX, Huang J, Ryan SF (1996) Effects of human polymorphonuclear leukocyte elastase upon surfactant proteins in vitro. Biochim Biophys Acta 1302: 117–128
Tittball RW (1993) Bacterial phospholipases C. Microbiol Rev 57: 347–366
Gilliard N, Heldt GP, Loredo J, et al (1994) Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties. J Clin Invest 93: 2608–2615
Viuff B, Aasted B, Alexandersen S (1994) Role of alveolar type II cells and of surfactant-associated protein C mRNA levels in the pathogenesis of respiratory distress in mink kits infected with aleutian mink disease parvovirus. J Virol 68: 2720–2725
Grimm C, Longmore WJ (1995) Sublethal hydrogen peroxide inhibits alveolar type II cell surfactant phopholipid biosynthetic enzymes. Am J Phys 268: L129–L135
Azghani AO, Connely JC, Peterson BT, Gray LD, Collins ML, Johnson AR (1990) Effects of Pseudomonas aeruginosa elastase on alveolar epithelial permeability in guinea pigs. Infect Immun 58: 433–438
Stinson SF, Ryan DP, Hertweck MS, Hardy JD, Hwang-Kow SY, Loosli CG (1976) Epithelial and surfactant changes in influenza) pulmonary lesions. Arch Pathol Lab Med 100: 147–153
Engen RL, Brown TT (1991) Changes in phospholipids of alveolar lining material in calves after aerosol exposure to bovine herpes virus-1 or parainfluenza-3 virus. Am J Vet Res 52: 675–677
Rose M, Lindberg DAB (1968) Effect of pulmonary pathogens on surfactant. Dis Chest 53: 541–544
Jaeger KE, Kinscher DA, König B, König W (1992) Extracellular lipase of Pseudomonas aeruginosa: Biochemistry and potential role as a virulence factor. In: Hoiby N, Pedersen SS (eds) Cystic Fibrosis, Basic and Clinical Research. Elsevier, Amsterdam, pp 113–119
King RJ, Coalson JJ, Seidenfeld JJ, Anzueto AR, Smith DB, Peters JI (1989) 02 and pneumonia-induced lung injury II. Properties of pulmonary surfactant. J Appl Physiol 67: 357–365
Coalson JJ, King RI, Winter VT, et al (1989) OZ and pneumonia-induced lung injury I. Pathological and morphometric studies. J Appl Physiol 67: 346–356
Sachse K (1989) Changes in the relative concentrations of surfactant phospholipids in young pigs with experimental pneumonia. J Vet Med 36: 385–390
Akino T (1992) Lipid, components of the surfactant system. In: Robertson B, Van Golde LMG, Batenburg JJ (eds) Pulmonary surfactant: From molecular biology to clinical practice. Elsevier, Amsterdam, pp 19–31
Tahvanainen J, Hallman M (1987) Surfactant abnormality after endotoxin-induced lung injury in guinea-pigs. Eur J Respir Dis 71: 250–258
Brade H, Brade L, Schade U, et al (1987) Structure, endotoxicity, immunogenicity and antigenicity of bacterial lipopolysaccharides (Endotoxins, 0-Antigens). In: Levin J, Ten Cate JW, Buller HR, et al (eds) Bacterial endotoxins: Pathophysiological effects, clinical significance, and pharmacological controll. Alan R Liss Inc, New York, pp 17–45
Kalina M, Blau H, Riklis S, Kravtsov V (1995) Interaction of surfactant protein A with bacterial lipopolysaccharide may affect some biological functions. Am J Physiol 268: L144–L151
Van Iwaarden JF, Pikaar JC, Storm J, et al (1994) Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides. Biochem J 303: 407–411
Kuan SF, Rust K, Crouch E (1992) Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest 90: 97–106
Lopez A, Albassam M, Yong S, Sharma A, Lillie LE, Prior MG (1987) Profiles of type-II pneumocytes in rats inoculated intratracheally with bacterial lipopolysaccharide. Am J Vet Res 48: 1534–1539
Somerson NL, Kontras SB, Pollack JD, Weiss HS (1971) Pulmonary compliance: Alteration during infection. Science 171: 66–68
Von Wichert P, Wilke A (1976) Alveolar stability and phospholipid content in normal pig lungs and in pig lungs with Mycoplasma pneumonia. Scand J Respir Dis 57: 25–30
Yoneda K, Walzer PD (1981) Mechanisms of pulmonary alveolar injury in experimental Pneumocystis carinii pneumonia in the rat. Br J Exp Path 62: 339–346
Sheehan PM, Stokes DC,Yeh YY, Hughes WT (1986) Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia. Am Rev Respir Dis 134: 526–531
Kernbaum S, Masliah J, Alcindor LG, Bouton C, Christol D (1983) Phospholipase activities of bronchoalveolar lavage fluid in rat Pneumocystis carinii pneumonia. Br J Exp Path 64: 75–80
Phelps DS, Umstead TM, Rose RM, Fishman JA (1996) Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat. Eur Respir J 9: 565–570
O’Riordan DM, Standing JE, Kwon KY, Chang D, Crouch EC, Limper AH (1995) Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 95: 2699–2710
Zimmerman PE, Voelker DR, McCormack FX, Paulsrud JR, Martin WI (1992) 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A. J Clin Invest 89: 143–149
Williams MD, Wright JR, March KL, Martin WJ (1996) Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Am J Respir Cell Mol Biol 14: 232–238
Limper AH, Crouch EC, O’Riordan DM, et al (1995) Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages. J Lab Clin Med 126: 416–422
Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L (1982) Evidence of lung surfactant abnormality in respiratory failure. Study of broncholaveolar lavage phospholipids, surface activity, phospholipase activity and plasma myoinositol. J Clin Invest 70: 673–683
Baughman RP, Stein E, MacGee J, Rashkin M, Sahebjami H (1984) Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin Chem 30: 521–523
Baughman RP, Sternberg RI, Hull W, Buchsbaum JA, Whitsett J (1993) Decreased surfactant protein A in patients with bacterial pneumonia. Am Rev Respir Dis 147: 653–657
Günther A, Siebert C, Schmidt R, et al (1996) Surfactant alterations in severe pneumonia, acute respiratory distress syndrome and cardiogenic lung edema. Am J Respir Crit Care Med 153: 176–184
LeVine AM, Lotze A, Stanley S, et al (1996) Surfactant content in children with inflammatory lung disease. Crit Care Med 24: 1062–1067
Hoffman AGD, Lawrence MG, Ognibene FP, et al (1992) Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 102: 1730–1736
Escamilla R, Prevost MC, Hermant C, Caratero A, Cariven C, Krempf M (1992) Surfactant analysis during Pneumocystis carinii pneumonia in HIV-infected patients. Chest 101: 1558–1562
Rose RM, Catalano PJ, Koziel H, Furlong ST (1994) Abnormal lipid composition of bronchoalveolar lavage fluid obtained from individuals with AIDS-related lung disease. Am J Respir Crit Care Med 149: 332–338
Sternberg RI, Whitsett JA, Hull WM, Baughman RP (1995) Pneumocystis carinii alters surfactant protein A concentrations in bronchoalveolar lavage fluid. J Lab Clin Med 125: 462–469
Phelps DS, Rose RM (1991) Increased recovery of surfactant protein A in AIDS-related pneumonia. Am Rev Respir Dis 43: 1072–1075
Meignan M, Guillon JM, Denis M, et al (1990) Increased lung epithelial permeability in HIV-infected patients with isolated cytotoxic T-lymphocytic alveolitis. Am Rev Respir Dis 141: 1241–1248
Jobe AH (1993) Pulmonary surfactant therapy. N Engl J Med 328: 861–868
Johanson WG (1991) Bacterial infection in adult respiratory distress syndrome. In: Zapol M, Lemaire F (eds) Adult Respiratory Distress Syndrome, volume 50. Marcel Dekker, New York, pp 77–89
Van Daal GJ, Eijking EP, So KL, et al (1992) Acute respiratory failure during pneumonia induced by sendai virus. Adv Exp Med Biol 316: 319–326
Van Daal GJ, So KL, Gommers D, et al (1991) Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg 72: 589–595
Eijking EP, Van Daal GJ, Tenbrinck R, et al (1991) Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med 17: 475–478
Van Daal GJ, Bos JAH, Eijking EP, Gommers D, Hannappel E, Lachmann B (1992) Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis 145: 859–863
Van ‘t Veen A, Hendrik ER, Gommers D, Mouton JW, Lachmann B (1994) Surfactant therapy enhances survival of influenza A infected mice. Intensive Care Med 20: S58 (Abst)
Tashiro K, Li WZ, Yamada K, Matsumoto Y, Kobayashi T (1995) Surfactant replacement reverses respiratory failure induced by intratracheal endotoxin in rats. Crit Care Med 23: 149–156.
Tashiro K, Yamada K, Li WZ, Matsumoto Y, Kobayashi T (1996) Aerosolized and instilled surfactant therapies for acute lung injury caused by intratracheal endotoxin in rats. Crit Care Med 24: 488–494
Buheitel G, Scharf J, Harms D (1992) Erfahrungen mit der Surfactanttherapie des adulten Atemnotsyndroms ( ARDS ). Monatsschr Kinderheilkd 140: 629–632
Harms K, Herting E (1994) Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration 61: 348–352
Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL (1991) Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87: 101–107
Wilson DF, Jiao JH, Bauman LA, et al (1996) Calf’s lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 24: 1316–1322
Mikawa K, Maekawa N. Nishina K, Takao Y, Yaku H, Obara H (1993) Selective intrabronchial instillation in a patient with pneumonia: A preliminary report. Eur Respir J 6: 1563–1566
Touw DJ, Brimicombe RW, Hodson ME, Heijerman HGM, Bakker W (1995) Inhalation of antibiotics incysticfibrosis.Eur Respir J 8: 1594–1604
Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Davies ER, Carswell F (1994) The quantitative distributon of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 88: 203–211
Ilowite JS, Gorvay JD, Smaldone GC (1987) Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 136: 1445–1449
Brain JD, Knudson DE, Sorokin SP, Dabis MA (1976) Pulmonary distribution of particies given by intratracheal instillation or by aerosol inhalation. Environ Res 11: 13–33
Liu M, Wang L, Li E, Enhorning G (1991) Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol 71: 742–748
Van ‘t Veen A, Mouton JW, Gommers D, Kluytmans JAJW, Dekkers P, Lachmann B (1995) Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother 39: 329–333
Van ‘t Veen A, Gommers D, Mouton JW, Kluytmans JAJW, Krijt EJ, Lachmann B (1996). Exogenous pulmonary surfactant as a drug delivering agent: Influence of antibiotics on surfactant activity. Br J Pharmacol 118: 595–598
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
van’t Veen, A., Gommers, D., Lachmann, B. (1997). Rationale for Surfactant Therapy in Pneumonia. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1997. Yearbook of Intensive Care and Emergency Medicine, vol 1997. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-13450-4_53
Download citation
DOI: https://doi.org/10.1007/978-3-662-13450-4_53
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-13452-8
Online ISBN: 978-3-662-13450-4
eBook Packages: Springer Book Archive